DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3

Information source: Hospital de Clinicas de Porto Alegre
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Spinocerebellar Ataxia Type 3; Machado Joseph Disease

Intervention: Lithium Carbonate (Drug); Placebo (Drug)

Phase: Phase 2/Phase 3

Status: Completed

Sponsored by: Hospital de Clinicas de Porto Alegre

Official(s) and/or principal investigator(s):
Laura B Jardim, MD PhD, Principal Investigator, Affiliation: Medical Genetics Service Hospital de Clinicas de Porto Alegre
Jonas AM Saute, MD, Study Director, Affiliation: Neurology Service Hospital de Clínicas de Porto Alegre

Summary

Design: Phase II-III, double-blind, parallel, placebo controlled randomized Clinical trial Background: Spinocerebellar ataxia type 3 (SCA-3) is an autosomal dominant adult-onset neurodegenerative disorder for which there is no current treatment. Patients will invariably become dependent from others and unable to walk during the disease course. Hypothesis: Lithium Carbonate is safe and effective in treating neurological symptoms and improving quality of life of patients with SCA3. Outcomes: Primary

- Phase 2 - To assess safety and tolerability of Lithium Carbonate in patients with SCA3

after 6 months of follow-up

- Phase 3 (if Phase II study shows safety of therapy) - To assess efficacy of Lithium

Carbonate in patients with SCA3 through the Neurological Examination Score for SCA 3 (NESSCA) after 12 months of follow-up . Secondary

1. - To assess efficacy on neurological function, ataxic, depressive and quality of life

scores of Lithium Carbonate in patients with SCA3 through the Scale for the Assessment and Rating of Ataxia (SARA), 9-Hole Peg Board test, 8m walking time, PATA repetition rate, Click Test, SCA Functional Index (SCAFI), Composite Cerebellar Functional Score (CCFS), Beck Depression Inventory, Barthel Index and WHOQol after 6 and 12 months of follow-up.

2. - To assess the effect of Lithium Carbonate in peripheral levels and expression of

treatment biomarkers (BDNF, NSE, HDAC, GSK-3Beta) Study Duration: 12 months

- Final analysis of phase 2 (safety study) at 6 months with continuous monitoring until

the end of phase 3 (efficacy study).

- Preliminary analysis of efficacy on ataxia scales at 6 months of study and final

analysis of phase 3 at 12 months. Obs: A futility analysis will be performed after 12 months of therapy if no statistically significant difference between groups were found. This analysis will define if the study will continue until 18 or 24 months of follow-up or will be ended at 12 months. Location: Hospital de Clínicas de Porto Alegre Subjects: 60 molecularly diagnosed SCA3 patients from the outpatient unit of the Medical Genetics Service of Hospital de Clínicas de Porto Alegre Intervention: Lithium Carbonate tablets of 300mg. Starting dose will be 300mg/day with drug titration during 49 days or until achieving the defined target lithium serum level of 0. 5 to 0. 8 mEq/L

Clinical Details

Official title: Randomized Clinical Trial to Assess the Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome:

Phase 2 - Safety and tolerability of Lithium Carbonate treatment in patients with SCA3

Phase 3 - Efficacy of Lithium Carbonate treatment in patients with SCA3

Secondary outcome:

Efficacy of Lithium Carbonate in patients with SCA3 on neurological function, ataxic, depressive and quality of life scores

Effect of Lithium Carbonate treatment in peripheral levels and expression of treatment biomarkers

Eligibility

Minimum age: 16 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Prior molecular diagnose of SCA3 with determined number of CAG expanded repeat.

- Not restricted to wheelchair.

- With disease duration between 2 and 10 years and more than 16 years old.

Exclusion Criteria:

- Signs of cardiopathy, elevated levels of creatinine, transaminases, bilirubins more

than 1. 5 times the normal upper limit at baseline.

- History of previous lithium carbonate significant adverse reaction, or drug abuse or

alcoholism.

- Disturbance of thyroid function at baseline.

- Participation on another clinical trial less than 4 weeks before the study entrance.

- Current use of valproic acid, memantine, neuroleptics and anticoagulants

- If the individual (woman) did not agree in utilize a high effective contraceptive

method during the study period and 3 months after the study-end.

Locations and Contacts

Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul 90035-903, Brazil
Additional Information

Related publications:

Watase K, Gatchel JR, Sun Y, Emamian E, Atkinson R, Richman R, Mizusawa H, Orr HT, Shaw C, Zoghbi HY. Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med. 2007 May;4(5):e182.

Starting date: May 2011
Last updated: January 29, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017